(firstQuint)Study to Evaluate the Effect of FX006 on Synovial Inflammation in Patients With OA of the Knee.

 This is an open-label study assessing the effect of the administration of a single intra-articular (IA) injection of FX006 32 mg on synovial volume in patients with osteoarthritis (OA) of the knee.

 The study will be conducted in male and female patients who are 40 years of age.

 Eligible patients who provide written consent and meet all entry criteria will undergo initial ultrasound examination and MRI with contrast of the index knee, and then receive a single IA injection of FX006 administered to the index knee at Baseline/Day 1.

 Patients will return to the clinic at Weeks 6 and 24 for an MRI with contrast of the index knee and other assessments.

 In addition, a patient questionnaire will be administered and adverse events (AEs) and concomitant medication updates will be collected via telephone at Weeks 12 and 18.

 The study is expected to enroll over approximately 6 months.

.

 Study to Evaluate the Effect of FX006 on Synovial Inflammation in Patients With OA of the Knee@highlight

This is an open-label study assessing the effect of the administration of a single intra-articular (IA) injection of FX006 32 mg on synovial volume in patients with osteoarthritis (OA) of the knee.

